Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group Review uri icon

Overview

MeSH Major

  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • Methodology to show that an intervention alters the natural history of prostate cancer is described. At each stage of development, only agents with sufficient activity should be moved forward.

publication date

  • December 2004

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2004.07.099

PubMed ID

  • 14752077

Additional Document Info

start page

  • 537

end page

  • 56

volume

  • 22

number

  • 3